Logo

ONMDW

OneMedNet Corporation

ONMDW

OneMedNet Corporation • NASDAQ
$0.18 ▲ 43.85% (+0.05)
Market Cap $156.17 M
52w High $0.18
52w Low $0.14
Dividend Yield 0%
P/E 0
Volume 125.74K
Outstanding Shares 889.85M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $177K ▲ $2.003M ▲ $-741K ▼ -418.644% ▼ $-0.02 ▼ $-725K ▼
Q2-2025 $155K ▲ $1.822M ▼ $2.982M ▲ 1.924K% ▲ $0.081 ▲ $3.038M ▲
Q1-2025 $137K ▲ $2M ▼ $-1.902M ▲ -1.388K% ▲ $-0.056 ▲ $-1.859M ▲
Q4-2024 $26K ▼ $2.614M ▲ $-2.374M ▼ -9.131K% ▼ $-0.085 ▼ $-2.319M ▼
Q3-2024 $142K $2.303M $-2.058M -1.449K% $-0.074 $-2.012M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $149K ▼ $1.506M ▼ $5.445M ▼ $-3.939M ▼
Q2-2025 $1.72M ▲ $2.337M ▲ $6.177M ▼ $-3.84M ▲
Q1-2025 $937K ▼ $1.732M ▼ $18.282M ▼ $-16.55M ▼
Q4-2024 $3.021M ▼ $3.727M ▼ $19.677M ▲ $-15.95M ▼
Q3-2024 $4.09M $4.388M $18.656M $-14.268M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-741K ▼ $-1.558M ▲ $1.108M ▲ $477K ▼ $27K ▲ $-1.558M ▲
Q2-2025 $2.982M ▲ $-2.284M ▼ $-670K ▼ $2.932M ▲ $-22K ▲ $-2.287M ▼
Q1-2025 $-1.902M ▲ $-1.948M ▲ $1.92M ▲ $0 ▲ $-28K ▲ $-1.953M ▲
Q4-2024 $-2.374M ▼ $-2.027M ▼ $365K ▲ $-100K ▼ $-1.762M ▼ $-2.062M ▼
Q3-2024 $-2.057M $-1.903M $-2.34M $5.47M $1.227M $-1.912M

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Subscription Revenue
Subscription Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement The company looks like a very early‑stage or pre‑commercial business. Over the past several years it has effectively reported no meaningful revenue, while still recording operating losses every year. That means the business model is not yet proven financially, and the company is still in “build and invest” mode rather than “scale and earn” mode. Earnings per share have swung sharply from year to year, which often signals one‑time items, capital structure changes, or listing‑related costs layered on top of a very small base of activity. Overall, the income statement points to a company that is still burning money with no clear revenue traction yet visible in the historical data.

Balance Sheet

Balance Sheet The balance sheet appears extremely thin, with no real asset or cash base showing up in the summary data and only a small amount of debt. Equity is negative, which typically indicates accumulated losses that exceed the company’s contributed capital. In practical terms, this points to a financially fragile position: limited internal resources, dependence on supportive investors or new capital, and little cushion if operations run into delays. The structure is consistent with a young, niche technology company that has spent more on development and overhead than it has brought in so far.

Cash Flow

Cash Flow Cash flow from operations has been negative in most of the reported years, and free cash flow follows the same pattern. There is essentially no spending on heavy equipment or physical assets, so the cash burn is mostly tied to people, technology, and overhead. This means the company is not self‑funding; it relies on outside financing to keep going. Without a growing revenue stream, continued negative operating cash flow would keep pressure on management to either raise more funds, cut spending, or restructure its plans.

Competitive Edge

Competitive Edge Competitively, OneMedNet is positioned in a specialized and promising niche: high‑quality medical imaging data used in real‑world clinical research. Its federated network of many provider sites and large imaging archive is a meaningful asset, because building such a network from scratch takes years and deep relationships. The focus on “regulatory‑grade” imaging data, combined with tools for secure de‑identification and curation, gives it a differentiated angle versus broader data aggregators. Long‑term arrangements with major device companies and an expansion into expert data annotation further strengthen its value proposition. That said, the overall real‑world data space is crowded with large, well‑funded players, so turning its niche strengths into durable, profitable market share will depend on execution and customer adoption.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of the story. The company has rebuilt its platform on top of Palantir’s technology, adding AI‑driven natural language search, rapid cohort building, and richer longitudinal insights. These features directly address pain points for pharma, device makers, and research organizations that need fast, precise access to complex imaging data. The Medcase partnership to add professional data annotation, plus cross‑industry anonymization services, shows management is trying to extend the technology into adjacent, higher‑value offerings. The big open question is how quickly and at what scale these innovations convert into steady, recurring revenue, and whether the company can sustain the required R&D and commercialization spending given its current financial constraints.

Summary

Overall, OneMedNet combines a weak current financial picture with a relatively strong technology and niche story. On the financial side, there is effectively no historical revenue, recurring operating losses, negative equity, and ongoing cash burn. This suggests high dependence on external capital and a narrow margin for error. On the strategic side, the company has built a specialized position in imaging‑based real‑world data, backed by a sizable provider network, AI‑enabled platform, and partnerships that could enhance its offering and support subscription‑style revenue in the future. The key tension is whether its innovative platform and differentiated data assets can be commercialized quickly and broadly enough to overcome its current financial fragility. Outcomes are likely to be highly sensitive to execution, customer uptake, and continued access to funding.